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Abstract
Background: During drug development, it is an impor-
tant safety factor to identify the potential of new molecu-
lar entities to become a victim of drug-drug interactions 
(DDIs). In preclinical development, however, anticipation 
of clinical DDIs remains challenging due to the lack of in 
vivo human pharmacokinetic data.
Methods: We applied a recently developed in vitro-in vivo 
extrapolation method, including hepatic metabolism and 
transport processes, herein referred to as the Extended 
Clearance Concept Classification System (ECCCS). The 
human hepatic clearances and the victim DDI potentials 
were predicted for atorvastatin, cerivastatin, fluvastatin, 
lovastatin acid, pitavastatin, pravastatin, rosuvastatin, 
and simvastatin acid.
Results: Hepatic statin clearances were well-predicted 
by the ECCCS with six out of eight clearances projected 
within a two-fold deviation to reported values. In addi-
tion, worst-case DDI predictions were projected for each 
statin. Based on the ECCCS class assignment (4 classes), 
the mechanistic interplay of metabolic and transport pro-
cesses, resulting in different DDI risks, was well-reflected 
by our model. Furthermore, predictions of clinically 
observed statins DDIs in combination with relevant per-
petrator drugs showed good quantitative correlations with 
clinical observations.
Conclusions: The ECCCS represents a powerful tool to 
anticipate the DDI potential of victim drugs based on 
in vitro drug metabolism and transport data.
Keywords: clearance prediction; drug-drug interactions 
(DDIs) prediction; in vitro-in vivo extrapolation (IVIVE); 
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Introduction
Statins are 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-
CoA) reductase inhibitors indicated for the treatment of 
hypercholesterolemia [1]. They are widely used to lower 
the risk of cardiovascular disease. In 2012, rosuvastatin, 
simvastatin, and atorvastatin were among the 15 most 
prescribed drugs in the United States. Myotoxicity and 
rare cases of severe rhabdomyolysis are reported adverse 
events following statin treatment though. In 2001, ceriv-
astatin was therefore withdrawn from the market due to 
incidents of fatal rhabdomyolysis, which were partially 
attributed to drug-drug interactions (DDIs) following co-
medication with gemfibrozil [2].
For several statins, hepatic elimination is described 
as interplay of drug transport and metabolism processes. 
Expressed at the basolateral membrane of hepatocytes, 
the organic anion transporting polypeptides (OATP) 1B1, 
1B3, and 2B1 as well as the organic anion transporter 
(OAT) 2 and the sodium taurocholate co-transporting poly-
peptide (NTCP) are known to be involved in the hepatic 
uptake of various statins. Subsequent biliary secretion 
is mediated by apically expressed efflux transporters 
including P-glycoprotein (P-gp), the multidrug-resistance 
associated protein (MRP) 2, and the breast cancer resist-
ance protein (BCRP) [3]. Hepatic metabolism of statins 
is predominantly mediated by enzymes of the cyto-
chrome P450 (CYP) family including CYP3A4, CYP2C8, 
and CYP2C9 [1]. Moreover, glucuronidation mediated by 
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UDP-glucuronosyltransferases (UGTs) is involved in the 
metabolism of several statins [4]. Thus, each statin exhib-
its a unique and complex pharmacokinetic profile due to 
specific transporter- and/or enzyme-mediated clearance 
mechanisms (Table 1). Inhibition of one or several of these 
clearance pathways upon co-medication of the statins (so-
called victim drug) with a perpetrator compound might 
therefore ultimately result in alterations of drug exposure.
Recently, our group established a novel method to 
predict the human hepatic drug clearance based on a 
mechanistic in vitro-in vivo extrapolation (IVIVE) model 
[5, 6]. The approach is based on incorporation of in vitro 
data for all physiological hepatic drug elimination pro-
cesses into the extended mechanistic hepatic clearance 
model, allowing the assessment of the rate-determining 
hepatic clearance step. Based on this approach, drugs can 
be classified according to their in vitro determined major 
clearance mechanism. Similar to the Biopharmaceutics 
Drug Disposition Classification System (BDDCS), which is 
based on the extent of in vivo observed drug metabolism 
and in vitro solubility data [7], our approach from here 
on referred as Extended Clearance Concept Classifica-
tion System (ECCCS), categorizes drugs into four classes. 
For highly permeable class 1 and 2 compounds, metabo-
lism is projected as the major hepatic clearance process. 
While passive hepatic uptake is the rate-determining step 
for class 1 compounds, the sum of metabolism and efflux 
transporter-mediated biliary elimination is predicted to 
be rate-determining for class 2 compounds. Active hepatic 
uptake is predicted to be the rate-determining step for 
class 3 compounds, while the clearance of class 4 com-
pounds is dependent on the interplay of all processes 
involved in hepatic elimination (namely metabolism, 
uptake, and efflux). Thus, based on the extended mecha-
nistic clearance concept, application of the ECCCS allows 
for a compound-class dependent assessment of the DDI 
potential of (new) chemical entities.
In this study, we used statins as model drugs to further 
validate our new in vitro data-based extended mechanis-
tic hepatic clearance model. Human hepatic clearances 
were predicted for all marketed statins: atorvastatin, flu-
vastatin, lovastatin acid, pitavastatin, pravastatin, rosuv-
astatin, and simvastatin acid as well as for cerivastatin. 
Subsequently, we assessed the DDI potential of each statin 
by simulating inhibition of the relevant hepatic clearance 
processes. The predicted DDI effects were compared with 
reported AUC changes from clinical studies [8–10], and 
the underlying mechanisms driving the DDI potential for 
each statin were discussed within the frame of the ECCCS.
Materials and methods
Materials
[3H]atorvastatin calcium (0.37 MBq/nmol), [3H]cerivastatin sodium 
(0.185 MBq/nmol), [3H]fluvastatin sodium (0.74 MBq/nmol), [3H]lov-
astatin acid (0.37 MBq/nmol), [3H]pitavastatin calcium (0.185 MBq/
nmol), [3H]pravastatin sodium (0.185 MBq/nmol), [3H]rosuvasta-
tin calcium (0.37 MBq/nmol), and [3H]simvastatin acid (0.37 MBq/
nmol) were obtained from American Radiolabeled Chemicals, Inc. 
(Saint Louis, MO, USA). [3H]taurocholic acid (TCA; 0.185 MBq/nmol) 
was purchased from PerkinElmer (Boston, MA, USA). All other com-
pounds and reagents were of analytical grade and purchased from 
commercial sources. Human sandwich-cultured hepatocytes were 
purchased as B-CLEAR® kits from Qualyst, Inc. (Durham, NC, USA). 
Hepatocytes from five different donors were used in this study (all 
Caucasian females, average age of 61). Donor information for human 
suspension hepatocytes and liver microsomes were previously 
described in detail [11, 12].
Hepatic clearance prediction
According to the extended mechanistic clearance concept (Figure 1), 
the overall apparent hepatic intrinsic clearance can be described as 
follows [6]:
Table 1: Overview of active processes involved in statin transport and/or metabolism.
Compounds   MRP2  BCRP  P-gp   OATP1B1  OATP1B3  OATP2B1 or NTCP  OAT1  OAT3  CYP3A4  CYP2C8  CYP2C9  UGTs
Lovastatin acid   −   −   −   +   −   +   −   −   +   +   −   +
Simvastatin acid  −   −   −   +   +   +   −   −   +   +   −   +
Cerivastatin   −   +   +   +   −   +   −   −   +   +   −   −
Fluvastatin   −   +   −   +   +   +   −   −   +   +   +   −
Pitavastatin   −   +   −   +   +   +   −   −   −   −   +   +
Atorvastatin   +   +   +   +   +   −   −   −   +   −   −   −
Pravastatin   +   +   −   +   +   +   −   +   −   −   −   −
Rosuvastatin   +   +   +   +   +   +   +   +   −   −   +   +
+: Identified transporter/enzyme substrate (qualitative information) as available in the literature. (References and anticipated quantitative 
pathway contributions to overall drug elimination [as available] are given in the manuscript.) −: Not described.
Brought to you by | Universitaetsbibliothek Basel
Authenticated
Download Date | 4/29/19 4:52 PM
Kunze et al.: Hepatic clearance prediction and DDI assessment of statins      177
All values for CLint,met refer to incubations with human liver micro-
somes. Moreover, we assumed that efflux over the sinusoidal mem-
brane from hepatocytes back into the blood occurred via passive 
diffusion only (i.e., PSeff,act = 0) and that the passive sinusoidal efflux 
was equal to the passive influx (i.e., PSeff,pas = PSinf,pas). Subsequently, 
the hepatic in vivo clearance (CLh) was predicted based on the “well-
stirred liver” model as follows [6]:
 
h
h u,b in,f ,act inf,pas int ,sec int ,met
h inf ,pas int ,sec int ,met u,b in,f ,act inf ,pas int ,sec int ,met
CL
Q f ( PS PS ) (CL CL )
Q ( PS CL CL ) f ( PS PS ) (CL CL )
=
⋅ ⋅ + ⋅ +
⋅ + + + ⋅ + ⋅ +
 (2)
where Qh is the hepatic blood flow [20.7 mL/(min·kg)] and fu,b is 
the unbound fraction of statins in blood as reported in literature 
(Table 2).
DDI assessment
A perpetrator drug may inhibit all active clearance pathways con-
tributing to the total hepatic elimination of a substrate compound. 
Accordingly, based on Eq. 1, the overall apparent hepatic intrinsic 
clearance in the presence of a perpetrator (CLh,int,i) can be expressed 
as follows [6]:
 
h,int,i
i,inf in,f ,act inf,pas i,sec int,sec i,met int,met
inf,pas i,sec int,sec i,met int,met
CL
(( 1 f ) PS PS ) (( 1 f ) CL ( 1 f ) CL )
( PS ( 1 f ) CL ( 1 f ) CL )
=
− ⋅ + ⋅ − ⋅ + − ⋅
+ − ⋅ + − ⋅
 
(3)
where fi,inf, fi,sec, and fi,met denote the inhibited fractions of active 
influx, secretion, or metabolism, respectively. A value of zero thereby 
indicates no inhibition whereas a value of one refers to complete 
inhibition. Based on this relationship, the hepatic in vivo clearance 
in the presence of any perpetrator compound (CLh,i) can be calculated 
in accordance with Eq. 2.
Following oral administration of a drug and its perpetrator, 
assuming the presence of hepatic and a non-hepatic (e.g., renal) 
elimination pathways and that the perpetrator drug only affects active 
processes in the liver, the exposure (AUC) fold-change (expressed as 
AUCpo,i/AUCpo) can be described as follows [13]:
 
inf,act inf,pas int,sec int,met
h,int
eff,act eff,pas int,sec int,met
( PS PS ) (CL CL )
CL
( PS PS CL CL )
+ ⋅ +
=
+ + +
 
(1)
where PSinf,act and PSinf,pas are the active and passive hepatic influx 
clearances from the blood, respectively, CLint,sec is the intrinsic biliary 
secretion clearance, and CLint,met is the intrinsic metabolic clearance. 
PSeff,act and PSeff,pas describe the active and passive sinusoidal efflux 
from the hepatocytes back into the blood, respectively.
All above parameters were determined experimentally 
(Table  2) [5, 6, 12]. For the present assessment, in vitro transport 
and metabolism data were taken from different in-house and lit-
erature sources as summarized in the Supplementary Material, 
Table 1, that accompanies the article at http://www.degruyter.com/
view/j/dmdi.2015.30.issue-2/dmdi-2015-0003/dmdi-2015-0003.
xml?format=INT. PSinf,act and PSinf,pas data were assessed in sus-
pended hepatocytes using a standardized in-house method [12]. 
CLint,sec was determined in human sandwich-cultured hepatocyte 
incubations using the B-CLEAR® assay (single concentration deter-
minations at 0.1 μM) assuming that metabolism was negligible [6]. 
Blood
Liver
PSinf PSeff
CLint,met
CLint,sec
CLh,int
Portal vein
Hepatic artery Hepatic vein
Figure 1: Mechanisms of drug elimination in the liver according to 
the extended mechanistic clearance concept.
From the bloodstream, drugs are taken up into hepatocytes (PSinf) 
via transporters and/or passive diffusion, followed by intracellular 
metabolism (CLint,met) and/or active secretion into bile (CLint,sec). 
Additionally, drugs can be actively and/or passively effluxed back 
into the circulation via the sinusoidal membrane (PSeff). Conse-
quently, for each statin, the hepatic intrinsic clearance (CLh,int) 
results from the interplay of the underlying clearance processes 
(see Eq. 1).
Table 2: In vitro pharmacokinetic parameters.
Compounds  
 
Measured in house 
 
Obtained from literaturea
PSinf,act,in vitro, 
μL·min−1·106 cells
  PSinf,pas,in vitro, 
μL·min−1·106 cells
  CLint,sec,in vitro,  
μL·min−1·mgprot−1
CLint,met,in vitro, 
μL·min−1·mgprot−1
  fu,b 
(−)
Lovastatin acid   64.88  57.17  bld   337.00  0.08
Simvastatin acid  45.63  117.09  0.50   564.71  0.11
Cerivastatin   87.07  95.82  bld   34.40  0.02
Fluvastatin   85.95  127.94  bld   107.79  0.04
Pitavastatin   143.18  101.70  bld   12.96  0.07
Atorvastatin   55.15  22.69  3.75   47.41  0.08
Pravastatin   22.78  14.13  0.71   0.68  0.97
Rosuvastatin   10.69  9.73  1.90   1.13  0.17
aLiterature references are provided in the Supplementary Material (Table 1). bld, below limit of detection (zeroed for all subsequent 
calculations).
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po,i h,i
po h n,h h,i h n,h
AUC F 1
AUC F f CL /CL 1 f
= ⋅
⋅ + −
 
(4)
Fn,h is the fractional contribution of hepatic clearance to over-
all clearance. (Details for the clinical determination of fn,h are pro-
vided in the Supplementary Material, Table 2.) Fh ( = 1−CLh/Qh) and 
Fh,i ( = 1−CLh,i/Qh) are the fractions of the oral dose escaping hepatic 
firstpass in the absence and presence of a perpetrator, respectively.
Under the additional assumption that the liver is the only clear-
ance organ (i.e., fn,h = 1), Eq. 4 simplifies with [14]:
 
po,i h,int
po h,int,i
AUC CL
AUC CL
=
 
(5)
Statistical analysis
Linear correlation analyses were performed to obtain the regres-
sion equation and the correlation coefficient (R2) using Microsoft 
Excel. Average fold errors (afe), predicting the accuracy between the 
observed and predicted parameters, were calculated with [15]:
 
1 predictedlog
observedafe 10 N
∑
=  
(6)
Results
The experimentally determined in vitro parameters for 
hepatic influx, metabolism, and biliary secretion are 
listed in Table 2. The up-scaled process parameters, 
the projected overall apparent hepatic intrinsic clear-
ances according to Eq. 1 and the predicted in vivo hepatic 
organ clearances (CLh,pre) according to Eq. 2 are given in 
Table 3. Moreover, Table 3 lists the in vivo observed hepatic 
clearances (CLh,obs) which were derived from human mass 
balance studies taking the in vivo determined renal clear-
ances into account.
As shown in Table 3, the values for the different physio-
logical processes driving hepatic elimination differ sig-
nificantly for the eight statins in our dataset. Highest net 
hepatic influx values, exceeding 500 mL/(min·kg), were 
obtained for pitavastatin and fluvastatin, while prava-
statin and rosuvastatin showed comparatively low values 
[ < 100 mL/(min·kg)]. Simvastatin acid, cerivastatin, and 
fluvastatin exhibited a high contribution of passive influx 
to the total net influx (PSinf,pas > PSinf,act). The up-scaled 
CLint,met ranged from 0.9 mL/(min·kg) for pravastatin to 
769.2 mL/(min·kg) for simvastatin acid. Up-scaled CLint,sec 
was highest for atorvastatin [11.8 mL/(min·kg)] whereas 
no biliary secretion at all could be experimentally deter-
mined for lovastatin acid, cerivastatin, fluvastatin, and 
pitavastatin. The predicted intrinsic clearances ranged 
from 7.4 mL/(min·kg) measured for pravastatin to 298.6 
mL/(min·kg) obtained for simvastatin acid.
Anticipation of hepatic clearance
The correlation between the in vitro predicted and in vivo 
observed hepatic clearances is illustrated in Figure 2. Six 
out of eight statins (atorvastatin, fluvastatin, lovastatin 
acid, pitavastatin, pravastatin, and simvastatin acid) were 
predicted within two-fold deviation from the clinically 
observed value, while cerivastatin and rosuvastatin were 
under-predicted by more than two- and six-fold, respec-
tively. Excluding rosuvastatin a good overall accuracy of 
prediction is achieved as indicated by an average fold 
Table 3: Predicted pharmacokinetic parameters.
Compounds   ECCCS  PSact 
mL/(min·kg)
  PSpas 
mL/(min·kg)
  CLint,met 
mL/(min·kg)
  CLint,sec 
mL/(min·kg)
  CLh,int 
mL/(min·kg)
  CLh,pred 
mL/(min·kg)
  CLh,obsa 
mL/(min·kg)
Lovastatin acid   1  165.1  145.5  459.0  0.0  235.8  9.9  11.4
Simvastatin acid  1  116.1  297.9  769.2  1.7  298.6  12.7  25.2
Cerivastatin   2  221.5  243.8  46.9  0.0  75.0  1.4  3.4
Fluvastatin   2  218.7  325.5  146.8  0.0  169.2  5.1  7.0
Pitavastatin   2  364.3  258.7  17.7  0.0  39.8  2.5  3.5
Atorvastatin   4  140.4  57.7  64.6  11.8  112.9  6.5  5.9
Pravastatin   4  57.9  36.0  0.9  2.2  7.4  5.4  10.4
Rosuvastatin   4  27.2  24.8  1.5  5.7  11.8  1.8  12.2
aLiterature references and calculation details are provided in the Supplementary Material, Table 2. Up-scaling of the in vitro clearances 
(Table 2) to human in vivo organ level was performed with the help of the following scaling factors: 1.6 (mg protein)/(1·106 cells) and 
99 (106 cells)/(g liver) for suspended hepatocytes; 53 (mg protein)/(g liver) for liver microsomes; 116 (mg protein)/(g liver) for sandwich-
cultured hepatocytes and 25.7 (g liver)/(kg body weight) for liver weight [16, 17]. CLh,int and CLh,pred were calculated according to Eqs. 1 and 2, 
 respectively. Cut-off values for ECCCS class assignments were defined as previously described [6]: Class 1/2 if PSpas > 3 × Qh (20.7 mL/min/kg), 
otherwise class 3/4. Class 1/3 if 2 × PSeff  < (CLint,met+CLint,sec), otherwise class 2/4.
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other reasons eventually leading to IVIVE disconnects are 
discussed below.
Drug-drug interaction potential projections
Figure 3 depicts the predicted DDI potential of all statins 
in our dataset following oral administration according to 
Eqs. 1, 3 and 5 generally assuming significant (almost com-
plete) process inhibition of 90% (i.e., fi,inf = fi,met = fi,sec = 0.9) 
[6]. As illustrated, the impact of simultaneous inhibition of 
multiple clearance processes can for some statins (such as 
cerivastatin, fluvastatin, lovastatin acid, pitavastatin, and 
simvastatin acid) be anticipated from the product of the 
AUC ratios of the individual processes (i.e., inhibition of 
only influx, metabolism, or biliary secretion) whereas for 
another category of statins (such as atorvastatin, pravas-
tatin, and rosuvastatin) the projected overall AUC change 
increases over-proportionally compared to the single 
process contributions. The power of the extended hepatic 
clearance model for providing mechanistic insight into the 
(rate-determining) processes driving hepatic elimination 
and, ultimately, for assessing qualitatively and quantita-
tively the compound-dependent DDI risks is subsequently 
discussed for each statin separately (see also Table 1).
Lovastatin acid and simvastatin acid
Lovastatin and simvastatin are both administered as 
lactone pro-drugs, which are rapidly converted to their 
active acid forms either by spontaneous chemical reac-
tions or by carboxylesterase-mediated metabolism in 
error (afe) of 1.5 determined according to Eq. 6. However, 
in agreement with previous work, a trend toward a slight 
under-estimation of the in vivo observed hepatic clear-
ances was observed (linear regression slope: 0.47, inter-
cept: 1.72, R2 = 0.80) [5, 6]. It is noteworthy to mention at 
this point that according to ECCCS the quantitative hepatic 
clearance prediction of mainly class 2 and, probably, class 
4 compounds is highly sensitive to the intrinsic metabolic 
clearance input parameter as discussed in more detail 
elsewhere [6]. As we refer for the present manuscript to 
non-in-house CLint,met values from different literature 
sources (Supplementary Material, Table 1), the prediction 
accuracy might be impacted particularly for these two 
compound classes. (The uptake-limited ECCCS class 3 and 
4 compounds are much less sensitive to CLint,met). Possible 
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Figure 2: Correlation between the predicted (CLh,pred) and observed 
(CLh,obs) hepatic clearances.
ato, atorvastatin; cer, cerivastatin, flu, fluvastatin; lov, lovastatin 
acid; pit, pitavastatin; pra, pravastatin; ros, rosuvastatin and sim, 
simvastatin acid. The black and gray lines represent the line of unity 
and the two-fold deviations, respectively.
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the intestine, liver, and plasma [10, 15]. Renal clearance 
represents a minor elimination pathway for both lovasta-
tin acid and simvastatin acid with 10% and 13% parent 
drug excreted in urine, respectively. Both drugs are mainly 
eliminated by metabolism via CYP3A4, CYP2C8, and UGTs 
[4, 10, 15]. Lovastatin acid was in vitro identified to be 
transported by OATP1B1, and simvastatin acid is a sub-
strate of OATP1B1 and OATP1B3 [12].
Following co-medication with gemfibrozil in clinics, 
AUC ratios of 2.8 and 2.9 were reported for lovastatin 
acid and simvastatin acid, respectively [18, 19]. Gem-
fibrozil is a well-known inhibitor of OATP1B1, NTCP, 
CYP2C8, and UGTs [20, 21]. Accordingly, applying Eq. 5 
with fi,inf = fi,met = 0.9, AUC ratios of 6.1 and 4.7 are predicted 
for lovastatin acid and simvastatin acid, respectively. 
Both projections slightly over-predict the in vivo findings 
though (2.2-fold and 1.6-fold for lovastatin acid simvas-
tatin acid, respectively). However, static DDI prediction 
methods are generally expected to be over-predictive for 
the in vivo situation as they do not account for the real 
inhibitor concentration and consequently for partial 
inhibition effects at the sites of interaction (i.e., any 
process inhibition fractions below 0.9 in this study). In 
addition, recent studies in our laboratories have revealed 
the involvement of at least one additional not yet iden-
tified transporter system in the hepatic uptake of both 
compounds (its contribution to overall active uptake is 
estimated with about 80% for lovastatin acid and 40% 
for simvastatin acid) [12]. Provided that gemfibrozil is not 
inhibiting this additional transport system, the fractional 
contributions for active OATP1B1-mediated influx would 
be significantly lower than assumed above (fi,inf = 0.2 and 
0.6 for lovastatin acid and simvastatin acid, respectively) 
and, as a consequence, a lower DDI potential following 
simultaneous inhibition of OATP1B1-mediated hepatic 
uptake and overall metabolism is projected (3.5-fold for 
lovastatin acid and 4.2-fold for simvastatin acid).
Nevertheless, based on their high passive perme-
ability characteristics, both compounds were assigned to 
ECCCS class 1. In this class, the uptake into the hepatocytes 
becomes the rate-determining step of hepatic elimination, 
and metabolism is anticipated to be the major source for 
DDIs. Applying the mechanistic extended hepatic clear-
ance model, inhibition of only metabolism resulted in 
AUC ratio projections of 3.2 and 3.5 for lovastatin acid and 
simvastatin acid, respectively. This DDI prediction is in 
excellent agreement with the in vivo interaction results 
( < 1.2-fold over-predictive for both lovastatin acid as well 
as simvastatin acid). Consequently, in alignment with the 
ECCCS class 1 assignment, transporter effects (if any) are 
projected to be minimal and the product of the individual 
AUC ratio changes driving hepatic elimination (namely 
hepatic uptake and metabolism) can be used to anticipate 
the overall DDI risk following simultaneous inhibition of 
both processes together (Figure 3).
Cerivastatin
Cerivastatin, administered as a free acid, is exclusively 
eliminated in the liver where primary OATP1B1 (∼20%) 
and a yet unknown transporter system (∼80%) are 
involved in its active hepatic uptake [12]. Metabolism is 
the only reported clearance pathway of cerivastatin, with 
a contribution of 61% CYP2C8 and 37% of CYP3A4 [21, 22].
As shown in Table 3, cerivastatin was assigned to 
ECCCS class 2. In this class, the sum of metabolism and 
biliary clearance represents the rate-determining step 
of hepatic elimination and inhibition of metabolism is 
generally projected as the major source of drug-drug 
interactions (Figure 3). In clinical studies, an AUC-ratio 
of 5.6 has been observed following co-administration of 
cerivastatin and gemifbrozil [9]. Based on in vitro studies, 
gemfibrozil is a potent inhibitor of hepatic anion uptake 
transporters (OATPs, NTCP), as well as of CYP2C8-medi-
ated cerivastatin metabolism while its inhibitory effect 
on CYP3A4 is expected to be of minor clinical relevance 
[21, 23]. Thus, assuming complete inhibition of active 
cerivastatin uptake and CYP2C8-mediated metabolism by 
gemfibrozil (fi,inf = 0.9, fi,met = 0.61) the liver-based static DDI 
model (Eq. 5) predicted an AUC ratio of 4.1. Furthermore, 
in clinics, cyclosporine A (CsA, an OATP family, NTCP 
and CYP3A4 inhibitor with no relevant CYP2C8 effect) 
was shown to increase the AUC of cerivastatin by 3.8-fold 
[9]. Accordingly, with fi,inf = 0.9 and fi,met = 0.37, an AUC ratio 
of 2.6 is anticipated from in vitro data. Consequently, for 
both scenarios, DDI effects within a comparable range 
to the observed AUC ratios were predicted with a general 
trend toward a slight under-prediction (about 1.5-fold) 
of the effective DDI potential. One reason for systematic 
under-predictions with the extended clearance concept 
approach is the possibility that the fractional process con-
tributions as estimated from in vitro investigations might 
not absolutely reflect the ultimate in vivo situation cor-
rectly (e.g., wrong fractional contributions of known path-
ways, existence of additional not yet identified pathways 
and/or time-dependent changes of pathway contribu-
tions as, e.g., observed following auto-induction/inhibi-
tion). And indeed, being a prominent CYP3A4, BCRP, and 
P-gp substrate [24], for cerivastatin a possible existence 
of an extra-hepatic elimination pathway such as pre-
systemic intestinal metabolism and/or efflux ultimately 
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contributing to the overall clinical DDI risk in the range 
of our under-predictions was discussed in literature [9]. 
Nevertheless, similar to ECCCS class 1, transporter effects 
for ECCCS class 2 drugs are anticipated to contribute mini-
mally to their hepatic interaction risk, and the overall 
DDI potential as victim drug in the liver can easily be pro-
jected from the AUC changes of the individual processes 
(Figure 3).
Fluvastatin
Fluvastatin is predominately cleared by the liver. Adminis-
tered a as free acid, about 90% of a fluvastatin dose under-
goes metabolism while only 2% and 6% of parent drug are 
recovered in feces and urine, respectively. In vitro studies 
indicate that metabolism is primarily mediated by CYP2C9 
(75%) and to a lower extent by CYP3A4 (20%) and CYP2C8 
(5%) [25]. Moreover, OATP1B1, OATP2B1, OATP1B3, and 
NTCP contribute to the active hepatic uptake of fluvasta-
tin [12, 26, 27].
Fluvastatin was assigned to ECCCS class 2, and in 
agreement with this classification, the overall DDI poten-
tial can be projected from the individual process con-
tributions as discussed above (Figure 3). Inhibition of 
metabolism is predicted as the major pathway causing 
DDIs while inhibition of hepatic uptake transporters 
is expected to have a minor impact. This conclusion is 
supported by a clinical observation demonstrating that 
co-administration of the CYP3A4 and OATP transporter 
family inhibitor erythromycin (fi,met = 0.2, fi,inf = 0.9) did not 
significantly alter the exposure of fluvastatin (predicted 
and observed AUC ratio of 1.6 and 1.2, respectively) [25].
As illustrated in Figure 3, an AUC ratio of 11.3 was pro-
jected assuming simultaneous inhibition of active uptake 
and metabolism (fi,inf = fi,met = 0.9). In clinical trials, maximal 
DDI effects resulted generally in AUC ratios below 4 
though. However, as multiple transporters and meta-
bolic enzymes are involved in the hepatic elimination of 
fluvastatin, it is likely that perpetrators used in clinical 
studies did not concomitantly inhibit all active clear-
ance processes involved in its elimination. For example, 
AUC-increases of up to 3.5-fold have been reported for co-
administration of fluvastatin with CsA (potent inhibitor 
of OATPs, NTCP, BCRP, and CYP3A4 [9]). Assuming inhi-
bition of hepatic uptake (fi,inf = 0.9) and simultaneously of 
only CYP3A4-mediated metabolism (fi,met = 0.2) the antici-
pated change in AUC is 1.8-fold which, in contrast to above 
projections, slightly under-predicts the in vivo observed 
value. Thus, the discrepancy between the predicted and 
observed clinical DDI effect could eventually be attributed 
to an additional (partial) inhibition of CYP2C8 and/or 
CYP2C9 by CsA. Recent investigations, however, are more 
supportive for the hypothesis that BCRP-mediated intes-
tinal efflux might have a significant role in modulating 
the absorption of fluvastatin [15]. Integrating into above 
assessment an experimentally determined in vivo expo-
sure increase of 72% (1.72-fold) following complete BCRP 
inhibition, the overall static DDI risk projection for fluvas-
tatin in the presence of CsA would be 3.1-fold which is in 
good compliance with the clinical observations.
Pitavastatin
Administered as a free acid, pitavastatin is exclusively 
eliminated via the liver, and 79% of the dose is recovered in 
feces as unchanged parent drug, indicating direct biliary 
secretion [15]. Thus, metabolism of pitavastatin, mainly 
mediated by CYP2C9 (45%) and UGT (55%), is described 
as a minor hepatic elimination pathway [1, 28]. Moreover, 
pitavastatin is an in vitro substrate of OATP1B1, OATP1B3, 
NTCP, and BCRP [12, 22, 26, 29].
In contrast to the described clinical observations, no 
active biliary secretion of pitavastatin was measured in our 
in vitro experiments which is in alignment with recent clin-
ical findings that pitavastatin disposition is not influenced 
by BCRP in vivo [15]. Metabolism was predicted as the 
predominant hepatic elimination pathway of pitavastatin 
(Table 3), and the anticipated hepatic clearance based on 
the extended clearance concept equation was similar to 
the measured clinical data. This observation suggests that 
the reported value for biliary parent drug secretion (79%) 
might not correctly reflect the effective mechanism of pita-
vastatin elimination [15]. In vitro studies demonstrated 
that direct glucuronidation contributes significantly to 
pitavastatin metabolism. We therefore suggest that pita-
vastatin might be substantially biliary secreted in vivo as 
its direct glucuronide metabolite [1, 28, 30]. Since glucuro-
nide metabolites are often found to be cleaved in the gas-
trointestinal tract (e.g., by enterobacteria), the amount of 
unchanged pitavastatin found in human feces might con-
sequently not fully represent the actual amount of secreted 
parent drug. The contribution of direct biliary pitavastatin 
secretion in vivo might therefore be significantly overesti-
mated while hepatic metabolism is in fact representing the 
most relevant clearance mechanism.
Using the ECCCS categorization approach, pitavasta-
tin was assigned to class 2. Inhibiting all hepatic pitavas-
tatin clearance mechanisms as a worst-case scenario (i.e., 
fi,inf = fi,met = 0.9), we predicted an AUC ratio of 19.9 (Figure 3). 
In a clinical study, co-administration with CsA led to a 
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4.6-fold increased AUC of pitavastatin [9]. Based on in vitro 
inhibition data, CsA is expected to inhibit active hepatic 
uptake and UGT-mediated metabolism of pitavastatin 
while it has no clinically significant inhibitory potential 
on CYP2C9 [9, 31]. Thus, applying the known inhibitory 
properties of CsA (fi,inf = 0.9 and fi,met = 0.55), we forecast an 
AUC increase of 4.5-fold. In a different study, co-admin-
istration of pitavastatin with erythromycin (inhibitor of 
CYP3A4 and OATPs) resulted in an observed AUC increase 
of 380% [15]. Assuming inhibition of active hepatic influx 
only (fi,inf = 0.9), we project an AUC ratio of 2.1-fold. Our pre-
dictions indicate that clinically observed DDI effects are 
mechanistically well-reflected by our model. These obser-
vations further support the above mentioned hypothesis 
that clinical data might represent an over-estimation of 
the actual in vivo observed biliary pitavastatin clearance.
Atorvastatin
In clinics, atorvastatin is administered as a pharmaco-
logically active acid. About 70% of administered atorvas-
tatin is metabolized (mainly by CYP3A4), and about 28% 
are actively biliary secreted. With 2% of unchanged drug 
recovered in urine, renal elimination is a minor excretion 
pathway for atorvastatin. In vitro studies demonstrated 
that atorvastatin is a substrate for OATP1B1, OATP1B3, 
P-gp, BCRP, and MRP2 [3, 12, 32].
Based on in vitro data, atorvastatin was assigned to 
ECCCS 4 (Table 3). As shown in Figure 3, inhibition of 
either active influx (fi,inf = 0.9) or metabolism (fi,met = 0.9) is 
predicted to result in moderate AUC changes of about 2- 
to 3-fold, while no significant increase in AUC was antici-
pated when only biliary clearance was inhibited (fi,sec = 0.9). 
Upon simultaneous inhibition of all hepatic clearance 
processes, an AUC change of 13.5-fold is projected. Clini-
cal studies, following oral co-administration of atorvas-
tatin with CsA, reported AUC changes of up to 15-fold [9, 
15]. CsA is a well-known (in vitro) inhibitor of OATP1B1, 
OATP2B1, OATP1B3, NTCP, P-gp, BCRP, and MRP2 trans-
porters, as well as of CYP3A4 and UGT metabolic enzymes 
[31, 33–36]. Hence, the present total hepatic worst-case 
DDI prediction of about 14-fold is in good agreement 
with the reported clinical observations. Similarly, when 
clinically co-administered with a combination of lopina-
vir and ritonavir a 5.9-fold AUC increase of atorvastatin 
was observed [9, 15]. Lopinavir is a potent OATP1B1 and 
OATP1B3 inhibitor while ritonavir also inhibits CYP3A4 
metabolism [37, 38]. Assuming concomitant significant 
inhibition of active influx and metabolism (fi,inf = fi,met = 0.9), 
the extended clearance concept anticipates an exposure 
increase of around 6.5-fold. Moreover, an AUC ratio of 3.3 
was reported for atorvastatin when given together with 
the potent CYP3A4 inhibitor itraconazole (has no effect 
on OATPs), which is also in good agreement with the pro-
jected value of 2.4-fold [9, 15]. In contrast to the ECCCS 
class 1 and 2 compounds discussed before, the overall 
DDI potential for atorvastatin cannot be projected from 
the AUC changes of the individual processes though as 
nicely illustrated in Figure  3. Hence, for ECCCS class 4 
compounds the substantial over-proportional increase 
in AUC upon simultaneous inhibition of uptake, efflux 
and metabolism derives from the essential interplay and 
interdependencies of all hepatic elimination pathways 
together. It is noteworthy to mention here, that in current 
DDI risk assessment potential involvement of basolat-
eral hepatic and/or apical intestinal efflux transporters 
as well as of intestinal enzymes was not  considered and 
that significant coincidental in  vivo  inhibition of any of 
these active processes by perpetrators drugs would ulti-
mately result in over- predictions of the effective interac-
tion potential for this ECCCS class 4 compound.
Pravastatin
Administered as a free acid, the major route of hepatic 
pravastatin elimination is biliary secretion of parent drug 
mediated by BCRP and MRP2. Hepatic oxidative metabo-
lism via CYPs is considered to be of minor importance 
since  < 10% of the dose is recovered as metabolites in 
feces [15, 29, 39, 40]. Furthermore, active hepatic uptake 
of pravastatin is mediated by OATP1B1, OATP1B3, and 
OATP2B1 [1, 12].
Applying Eq. 4, inhibition of all hepatic clearance 
processes (fi,inf = fi,met = fi,sec = 0.9) resulted in a maximal 
AUC increase projection of more than 20-fold (Figure 3). 
However, in contrast to other statins, pravastatin exhib-
its a unique pharmacokinetic profile due to a significant 
contribution of renal clearance (47%) to the total body 
clearance which represents a significant deviation from 
the assumptions made for Eq. 5 [15]. Hence, the fractional 
contribution of the hepatic pathway to overall pravas-
tatin elimination is only about 53% (fn,h = 0.53), and as a 
consequence according to Eq. 4, complete blockage of the 
hepatic elimination pathway is not expected to result in 
AUC changes beyond 2.6-fold. Clinical DDI studies with 
pravastatin and gemfibrozil reported 2-fold AUC changes 
[41, 42]. Gemfibrozil is a selective inhibitor of hepatic 
OATPs and of renal OAT3. Hence, a 1.7-fold decrease of 
renal pravastatin clearance was observed in clinics likely 
due to inhibition of OAT3 [42]. Assuming only inhibition 
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of active hepatic influx (fi,inf = 0.9), we calculated an AUC 
ratio of 1.6 with Eq. 4 providing a slight under-prediction 
of the clinical situation possibly due to cross-reactivity 
of gemfibrozil with renal OAT3. Furthermore, no signifi-
cant AUC increases were observed in clinics following 
co-administration of pravastatin with either itracona-
zole or fluconazole both compounds potent CYP3A4 and 
CYP2C9 inhibitors [9]. This observation was also reflected 
by our model since inhibition of metabolism alone did 
not predict any relevant AUC changes (1.1-fold). However, 
in clinics, AUC ratios of 10–23 were reported upon co-
administration of pravastatin with CsA (inhibitor of 
OATPs, NTCP, CYP3A4, UGTs, MRP2, and BCRP) exceed-
ing the theoretically possible hepatic DDI potential by 
up to 9-fold [9]. Yet, in humans, the renal excretion 
process is known to involve active transporter-mediated 
secretion as indicated by the estimated renal clearance 
(9.2 mL/(min·kg) corresponding to 47% of total clearance) 
 significantly exceeding (about 5-6-fold) the projected 
renal filtration clearance [∼1.7 mL/(min·kg)] calculated 
from the product of glomerular filtration rate [1.8 mL/
(min·kg)] and the fraction unbound in blood (fu,p = 0.97) 
[43]. The most likely reason for the obvious contradiction 
in data is therefore the contribution of a transporter medi-
ated active tubular secretion pathway coincidentally also 
inhibited by CsA. In literature, OAT3 has been suggested 
to be responsible for the basolateral uptake of pravastatin, 
as further supported by the DDI between gemfibrozil and 
pravastatin [42]. The transporter involved in its luminal 
efflux is yet to be identified [41]. MRP2 and/or BCRP are 
likely candidate transporters though, both well-known to 
be effectively inhibited by CsA. Assuming a 80% simulta-
neous inhibition of both hepatic as well as renal elimina-
tion pathways, the anticipated overall exposure increase 
can be estimated with around 9-fold (details are given in 
the Supplementary Material [Eq. 9, Table 3]). Following a 
90% inhibition of the overall clearance, the AUC increase 
is projected with already 19-fold (Supplementary Material 
[Eq. 9, Table 4]). This would be in close agreement with the 
observed in vivo DDI effect (measured in vivo AUC ratio/
predicted in vitro AUC ratio ≈  1.2). Owing the complex 
inhibition profile of CsA, a final assessment is diffi-
cult to develop though notably because of a potentially 
reduced pravastatin absorption due to intestinal MRP2 
as discussed in literature [15]. The restriction of pravas-
tatin absorption was quantified with 67% reflecting the 
observed AUC increase in individuals with a synonymous 
c1446C > G single nucleotide polymorphism in the ABCC2 
(MRP2) gene [44]. In any case, the hepatic DDI projections 
according to Eq. 5 provided above are therefore likely just 
accidentally reflecting the in vivo observations stressing 
out the need for a careful and integrated (pre)clinical data 
analysis for more complex chemical entities such as the 
ECCCS class 4 compound pravastatin. To elucidate the 
exact DDI mechanism in full detail would require further 
(mechanistic) clinical investigations.
Rosuvastatin
Rosuvastatin is administered as a free acid. The hepatic 
clearance of rosuvastatin accounts for approximately 70% 
(fn,h = 0.7) of the net body clearance while 30% are attrib-
uted to renal secretion of unchanged drug. Direct biliary 
secretion of unchanged rosuvastatin is reported as the 
major hepatic route of elimination. Thereby, OATP1B1, 
OATP1B3, OATP2B1 and NTCP are assumed to mediate 
active hepatic uptake, while secretion of rosuvastatin 
into bile is primary mediated via BCRP [15, 45]. Metabolic 
clearance, mainly by CYP2C9 and UGTs, is considered to 
play a minor role in rosuvastatin elimination [15, 23, 45].
A clinical AUC ratio of 2.1-fold was reported when 
co-administering rosuvastatin together with lopinavir 
(OATP family inhibitor) and ritonavir (CYP3A4 inhibitor) 
[9]. Since rosuvastatin is not metabolized by CYP3A4, the 
observed DDI effect is expected to result exclusively from 
inhibition of active hepatic uptake. Assuming signifi-
cant inhibition of hepatic influx (fi,inf = 0.9) and applying 
due to a significant renal clearance contribution Eq. 4, 
we foresee an 1.5-fold AUC change with this static model 
approach. Moreover, a triple combination of rosuvasta-
tin, azatanavir (OATP inhibitor), and ritonavir (OATP and 
CYP inhibitor) resulted in vivo in a 3.1-fold increased rosu-
vastatin AUC [9]. Both perpetrators do not affect canali-
cular efflux of rosuvastatin. The corresponding static 
DDI projection predicts an AUC ratio of 1.7. Furthermore, 
maximum clinical AUC increases of 7.1-fold were observed 
upon co-administration of rosuvastatin with CsA, which 
is expected to inhibit all active hepatic elimination pro-
cesses of rosuvastatin [9]. Simulating inhibition of all pos-
sibly involved hepatic clearance processes in our model, 
using Eq. 5 (which neglects the clearance pathway via the 
kidney), an exposure increase of up to 15-fold is projected 
(Figure 3). Also taking into consideration a renal clearance 
contribution according to Eq. 4, we predict a 3.1-fold AUC 
increase though. BCRP eventually plays a relevant role 
in the absorption of rosuvastatin in humans which was 
demonstrated to be ∼50% [15, 46]. With that, the maximal 
exposure increase following intestinal BCRP inhibition is 
2-fold (probably significantly less though as the physico-
chemical properties of this hydrophilic statin are unlikely 
accounting for a complete absorption even in the absence 
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of any efflux transporter activity). Consequently, the static 
DDI projection for CsA, taking into account DDI effects 
in the liver and intestine, would be 6.2-fold maximum, 
which is in good agreement with the clinical observations. 
However, also for rosuvastatin, a substantial active tubular 
secretion via the OAT1, OAT3, MRP2, BCRP as well as P-gp 
was demonstrated [47, 48]. Accounting for such an active 
tubular secretion pathway, similar to the pravastatin case 
above (i.e., 80% inhibition of overall systemic clearance 
without considering a potential intestinal interaction on 
BCRP), the overall DDI risk would be only slightly over-
estimated (∼1.5-fold). [Details are given in the Supplemen-
tary Material (Eq. 9, Table 3).] Yet, hepatic efflux across 
the sinusoidal membrane was demonstrated to contribute 
significantly to rosuvastatin disposition in sandwich-cul-
tured human hepatocytes and in rats [49, 50]. A parallel 
inhibition of canalicluar as well as of sinusoidal efflux by 
CsA would possibly account for the remaining overestima-
tion of the DDI risk. As the current approach is based on 
the assumption that PSinf is equal to PSeff, this represents a 
potential caveat of the current prediction method.
Rosuvastatin was assigned to ECCCS class 4. This is 
in line with clinical observations, demonstrating that con-
comitant inhibition of sinusoidal uptake, biliary secretion 
as well as metabolism pathways significantly define the 
complex hepatic DDI potential of rosuvastatin. Although 
the mechanism-based DDI assessment for the liver seems 
to reflect, the clinical observations pretty well (all hepatic 
projections based on Eq. 4 are only slightly under-predic-
tive [1.6-fold maximum]), the experimentally determined 
in vivo hepatic clearance of rosuvastatin was significantly 
under-predicted ( > 6-fold) by the extended clearance 
concept model (Figure 2). One possible explanation for 
this IVIVE disconnect would be an over-estimation of the 
in vivo hepatic clearance pathway as derived from experi-
mental clinical data. Hypothetically, the presence of an 
additional extra-hepatic/extra-renal elimination pathway 
(such as e.g., active BCRP-mediated intestinal secretion) 
could have resulted in such an over-estimation of the 
effective hepatic clearance without really impacting above 
static DDI assessments for the unspecific cross-reactive 
inhibitor CsA [51]. Yet, present hypothesis is in partial 
contradiction to above discussed (major) involvement 
of BCRP in rosuvastatin absorption as it would rather 
support a significant involvement of this efflux pump in 
hepatic, renal and intestinal systemic elimination, largely 
accounting for the 2.4-fold exposure difference observed 
in healthy volunteers and BCRP-deficient individuals [46]. 
Fractional process contributions as experimentally deter-
mined from in vitro investigations not correctly reflecting 
the ultimate in vivo situation might provide an alternative 
explanation for the observed data discrepancy. Recently, 
Jamei et  al. developed an IVIVE-based PBPK model for 
rosuvastatin [52]. Since experimental hepatic uptake data 
did not accurately predict the reported in vivo clearance of 
rosuvastatin, the authors used a top-down (fitted) value 
[PSinf,act = 222 μL/(min·106 cells)] which was 21-fold higher 
compared to our experimental data (Table 2). Replacing 
our in-house active hepatic uptake results with this tai-
lored value the current IVIVE model (Eq. 2) would have 
predicted a hepatic clearance of 10.8 mL/(min·kg) being 
in fair agreement with the observed in vivo clearance 
(Table 3). In addition, using Eq. 4 (i.e., not considering a 
possible interaction on the active renal tubular secretion 
pathway and not taking into account a possible intestinal 
BCRP inhibition), static DDI predictions including this 
new data point would have provided DDI estimations 
reflecting above in vivo observations very well (8.8-fold 
following complete process inhibition as observed with 
CsA, 4.1-fold for an OATP and CYP inhibition profile as 
seen with the azatanavir/ritonavir combo, and 3.8-fold 
following OATP inhibition with lopinavir). But, although 
intriguing prima facie, the potential role of renal and/
or intestinal transporter inhibition as discussed above 
remains to be clarified. In addition, this hypothesis 
would need to be substantiated by the involvement of a 
not yet identified sinusoidal active solute-carrier system 
(as most other statins can reasonably well predicted with 
current approach the candidate transporters are unlikely 
OATP1B1, OATP1B3, or NTCP) which in course of the iso-
lation and/or preparation process is ultimately heavily 
down-regulated in the in vitro hepatocyte systems and 
which in vivo is similarly subject to inhibition by above 
perpetrators.
Discussion
In agreement with the previous findings, by applying the 
extended mechanistic hepatic organ model, a very good 
in vitro-in vivo projection of the effective hepatic clearances 
for all marketed statins could be demonstrated. Similarly, 
using clinical in vivo observations and in vitro information 
about drug transport and metabolism characteristics, the 
DDI potential of these statins was successfully assessed and 
quantitatively evaluated in several retrospective analyses. 
The correlation between observed and predicted AUC ratios 
for different combinations of the investigated statins and 
perpetrator drugs is given in Figure 4 summarizing all rele-
vant DDI predictions according to Eqs. 4 and 5 as discussed 
above. Overall, the observed interaction effects were well-
predicted by the extended mechanistic hepatic clearance 
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comparatively high intrinsic (metabolic and/or sinusoidal 
efflux) clearance. For the three ECCCS class 4 compounds 
in the dataset (pravastatin, rosuvastatin, and atorvasta-
tin), we predicted highest AUC changes upon concomitant 
inhibition of hepatic uptake, biliary secretion and metab-
olism whereas inhibition of the single clearance path-
ways results in comparatively moderate AUC ratios. This 
concept was well reflected by our DDI predictions and is 
in good agreement with clinical DDI data.
The static baseline (or worst-case) DDI prediction 
approach as presented in this manuscript is well-known to 
provide only conservative estimates of the hepatic in vivo 
situation as it does not account for the (time-dependent) 
effective substrate and inhibitor concentrations at the 
effector site as well as the actual inhibitor potency (IC50 
or Ki) of the perpetrator drug as described previously [6]. 
Nevertheless, it is confidently offering a conceptual and 
educational DDI model, which gives some insights into 
the relative importance of different physiological pro-
cesses involved in drug clearance. It is also noteworthy to 
remember at this point that for present analysis intrinsic 
metabolic clearance data from different references were 
taken, possibly impacting the (hepatic clearance and, 
consequently, DDI) prediction accuracy of mainly ECCCS 
class 2 and 4 compounds as discussed above. In addi-
tion, the approach bases on transport and metabolism 
data determined in pools of human hepatocytes and liver 
microsomes from multiple donors [6, 12]. Differences in 
protein expression levels due to genetic polymorphism 
were therefore not actively taken into consideration. As 
polymorphism for some variants ultimately translates 
into activity changes, it is evident, that such alterations 
might impact the ECCCS class categorization, hepatic 
clearance prediction and/or the DDI projections for some 
statins in our dataset. Susceptibility toward this effect was 
e.g., reported for atorvastatin (144% greater mean AUC for 
the SLCO1B1 (OATP1B1) c.521CC genotype [53]), fluvas-
tatin (up to 3-fold differences in mean AUC according to 
the number of CYP2C9*3 alleles [54]), or rosuvastatin (AA 
haplotype individuals on ABCG2 (BCRP) c.421 exhibited 
∼2.4-fold higher AUC compared with individuals carrying 
the control haplotype [46]).
Conclusions
In summary, we have demonstrated the validity of the 
ECCCS as a bottom-up assessment for hepatic clearance 
and as a static “worst-case” model for DDI predictions 
purely from in vitro data. The ECCCS is therefore expected 
model as indicated by an afe of 1.3. Out of 16 DDIs, 14 were 
predicted within a two-fold error, and linear regression 
analysis revealed an almost 1-to-1 correlation (slope: 0.857, 
intercept: −0.2677, R2: 0.84). Excluding the interaction pre-
dictions for the ECCCS class 4 compounds pravastatin and 
rosuvastatin in the presence of CsA as perpetrator (legiti-
mated by the evident and significant under-prediction of 
the overall DDI risk due to cross-reactivity with renal and/or 
intestinal transporters as discussed above), all clinical DDI 
effects were projected within a two-fold error maximum 
(R2 of 0.89) underlying the validity of this static DDI predic-
tion approach to appropriately anticipate the DDI potential 
of victim drugs in the liver.
For the five statins assigned to ECCCS class 1 (lovas-
tatin acid and simvastatin acid) and ECCCS class 2 (flu-
vastatin, cerivastatin, and pitavastatin), metabolism 
was anticipated as major clearance mechanism primary 
responsible for causing DDIs. For compounds assigned 
to these classes, the overall DDI potential can easily be 
anticipated from the product of the AUC changes of the 
individual process. A similar overall DDI behavior would 
be anticipated for ECCCS class 3 statins with sinusoi-
dal transporter inhibition being the major mechanism 
causing the interaction though. However, none of the 
statins in this study could be assigned to this ECCCS 
class which, besides a significant active uptake contribu-
tion, is characterized by a low passive permeability and a 
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Figure 4: Correlation of all observed (AUCpo,obs,i/AUCpo,obs) vs. 
predicted (AUCpo,pred,i/AUCpo,pred) drug-drug interactions between 
statins and different perpetrator drugs according to Eq. 4 [applied 
for pravastatin (black diamonds) and rosuvastatin (black circles)] 
and Eq. 5 [used for lovastatin acid (black squares), simvastatin acid 
(gray squares), fluvastatin (gray diamonds), cerivastatin (black tri-
angles), pitavastatin (gray triangles) and atorvastatin (gray circles)].
For effective numbers, please refer to text. Predictions prone to 
misjudgment of the effective DDI potential while underlying some 
vital assumptions (such as the presence of alternative renal and/or 
intestinal active processes as discussed in the manuscript) were not 
considered. The black and gray lines represent the line of unity and 
the two-fold deviations, respectively.
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to be of great value for preclinical drug development, at 
a time when no human pharmacokinetic data are avail-
able. In addition, in combination with clinical (DDI) data 
applying a top-down approach, the ECCCS concept can be 
extremely helpful in identifying IVIVE disconnects and in 
revealing alternative elimination pathways. As such path-
ways are passively (by altering the individual fractional 
pathway contributions) and/or actively (by involvement of 
metabolism and/or transporter processes likewise being 
subject to interferences) contributing to the ultimate DDI 
risk of victim drugs their quantitative integration into 
static or even dynamic (e.g., with help of the population-
based simulator Simcyp®), pharmacokinetic models 
might be crucial for an appropriate assessment and final 
interpretation of clinical study results.
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